Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 11/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.38 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.38 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.38 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.38 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.38 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.38 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.38 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.38 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.38 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5223410 | 0.81 | CCR1 (0.41) | CCR1PDE4BKDM1AEPHX2CACNA1B | |
| SCHEMBL28718193 | 0.78 | KDM1A (0.40) | CCR1KDM1AEPHX2CACNA1BCACNB4 | |
| SCHEMBL13137376 | 0.74 | CCR1 (0.96) | CCR1 | |
| SCHEMBL13968163 | 0.74 | CCR1 (0.67) | CCR1 | |
| SCHEMBL13606430 | 0.74 | CCR1 (0.67) | CCR1 | |
| SCHEMBL9913805 | 0.73 | KDM1A (0.47) | KDM1AEPHX2CACNA1BCACNB4CACNA1A | |
| SCHEMBL9913881 | 0.73 | KDM1A (0.47) | KDM1AEPHX2CACNA1BCACNB4CACNA1A | |
| SCHEMBL13137381 | 0.72 | CCR1 (1.00) | CCR1 | |
| SCHEMBL5220841 | 0.72 | RBP4 (0.43) | CCR1EPHX2CACNA1BCACNB4CACNA1A | |
| SCHEMBL21436867 | 0.71 | GPR119 (0.57) | CACNA1BCACNB4CACNA1ACACNA1GCACNG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663966-B1 | 1,3-DISUBSTITUTED AZETIDINE DERIVATIVES FOR USE AS CCR-3 RECEPTOR ANTAGONISTS IN THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISEASES | NOVARTIS AG (CH) | 2007-06-20 | — | — | EP | disclosed |
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | LE GRAND DARREN M | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043013-A1 | 1,3 Disubstituted azetidine derivatives for use as ccr-3 receptor antagonists in the treatment of inflammatory and allergic diseases | CCR1, CCR3, CCR9 | CCR1 1/4885PDE4B 1327/4885KDM1A 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.